Loading clinical trials...
Loading clinical trials...
The overall goal of this study is to identify risk and prognosis factors of Interstitial Lung Disease (ILD) in patients with rheumatoid arthritis (RA).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
NCT07627542 · Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), and more
NCT07632872 · Rheumatoid Arthritis (RA), Rheumatoid Arthritis
NCT06733935 · Systemic Sclerosis, Idiopathic Inflammatory Myopathies, and more
NCT07455578 · Autoimmune Diseases, Rheumatoid Arthritis (RA), and more
NCT07615504 · Interstitial Lung Disease (ILD)
Bichat Hospital
Paris
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions